About
Life sciences and technology sector veteran with over 40 years of experience and multiple cross-border leadership roles. Currently Chairman of Silence Therapeutics and Executive Chairman of ReNeuron Group.
Experience
- Oxford BioDynamics PlcNon Executive Chairmancurrent2026 — present
- Tern PLC - we back growing IoT companiesNon Executive Directorcurrent2024 — present
- FivepHusionNon Executive Directorcurrent2023 — presentSydney, New South Wales, Australia
- Silence Therapeutics plc (NASDAQ)Interim Principle Executive Officer & Chairmancurrent2026 — presentLondon, Berlin and New York
- ReNeuron GroupNon Executive Chairmancurrent2021 — presentSwansea, Wales, United Kingdom
- AdAlta LtdNon Executive Director2024 — 2025
- Biomer Technology LtdFounder and Chairman2003 — 2024Runcorn, United Kingdom
- BiVictriX Therapeutics plc (LSE)Non Executive Director2021 — 2023Manchester Area, United Kingdom
- Kazia Therapeutics Limited (ASX & NASDAQ)Non Executive Chairman2017 — 2023Sydney, Australia
- Redx Pharma PLCNon Executive Chairman2017 — 2021Cheshire, United Kingdom
- e-Therapeutics PLCNon Executive Chairman2016 — 2020Oxford, United Kingdom
- Anatara Lifesciences LtdNon Executive Director2014 — 2018Brisbane, Australia
- Royal Holloway, University of LondonVice Chairman of Counsel2007 — 2018London Area, United Kingdom
- Premier Veterinary Group plc (Previously Ark Therapeutics plc)Chairman2015 — 2017Bristol, United Kingdom
- Benitec Biopharma Ltd (ASX:BLT; NASDAQ; BNTC)Non Executive Director2010 — 2016Sydney, Australia
- Tissue Therapies LimitedNon -Executive Director2012 — 2015Brisbane, Australia
- Ark Therapeutics plcExecutive Chairman2010 — 2015London, United Kingdom
- Powerstax LimitedNon Executive Director1997 — 2013Farnborough
- Phadia ABDirector2007 — 2010Uppsala, Sweden
- Silence Therapeutics plcExecutive Chairman2004 — 2010London, United Kingdom
- EDEN BIOPHARMA GROUP LIMITEDNon Executive Chairman2003 — 2007Liverpool, United Kingdom
- ANGLE PLCNon Executive Director2004 — 2006Guildford, United Kingdom
- Allergy Therapeutics LimitedGroup CEO2001 — 2002Worthing, England
- Quadrant Healthcare plcGroup CEO1995 — 2000Cambridge, United Kingdom
- Celltech Group plcExecutive Director1991 — 1995Slough, United Kingdom
- Reed Business PublishingManaging Director1990 — 1991Guildford, United Kingdom
- Hoffman La RocheSales & Marketing Director UK & Eire1987 — 1990Welwyn Garden City , UK
- Fisons Group PLCInternational Marketing Manager1984 — 1987Loughborough
- SandozSales & Marketing Positions1978 — 1984London, United Kingdom
- Syntex ProductsPharmaceutical Sales Representative1978South East England
- Bass CharringtonDistrict Sales Manager - Pub & Off Licence Division1976 — 1977London, United Kingdom
Skills & more
Debt RestructuringExecutive ManagementCorporate DevelopmentPrivate EquityCEOsBusiness StrategyBusiness DevelopmentBiotechnology26Lifesciences36Technology Transfer20Commercialization15Biopharmaceuticals39
+12 more
Drug DiscoveryClinical DevelopmentMolecular BiologyOncologyBiochemistryVenture CapitalR&DClinical TrialsStrategyPharmaceutical IndustryImmunodiagnosticsMedical DevicesFrom Iain's professional profile.
Colleagues at Tern
Frequently asked questions
- Who is Iain Ross?
- Life sciences and technology sector veteran with over 40 years of experience and multiple cross-border leadership roles. Currently Chairman of Silence Therapeutics and Executive Chairman of ReNeuron Group.
- Where does Iain Ross work?
- Iain Ross is Non-Executive Director at Tern.
- Where did Iain Ross go to school?
- Iain Ross studied at Royal Holloway, University of London (BSc & Fellow, Biochemistry); Institute of Directors (IoD) (Chartered Director & Fellow); Bolton School.
Same school
Also attended Royal Holloway, University of London45
Warda DiyarInvestor at 13books CapitalThapanawit JanthraInvestment Analyst at Beacon VCJohn TayDirector of Partnerships and Strategy at Tin Men CapitalYvette PasquaAdvisor & Tech Expert at Chloe CapitalKenneth LamExecutive Director, Fund Operations at The Spartan GroupJussi NunesFinance at SC Ventures
+ 39 more
Also attended Institute of Directors (IoD)22
Nora AlsarhanCEO at SVCAthary AlmubarakChief Strategy Officer at SVCAlexia FarrugiaInvestment Committee & Board at Kintaro CapitalJennifer McMahonPartner at Seroba Life SciencesBrian CummingsInvestment Director at Clarendon Fund Managers Ltd.Elaine CoughlanManaging Partner at Atlantic Bridge Ventures
)
+ 16 more
